FDA Accepts Mesoblast’s BLA for Remestemcel-L for Steroid-Refractory GvHD

News
Article

After 3 tries, Mesoblast finally has a PDUFA date for its MSC therapy.

Silviu Itescu, MBBS, FRACP, chief Executive Officer and Managing Director, Mesoblast

Silviu Itescu, MBBS, FRACP

The FDA has accepted Mesoblast’s biologics license application (BLA) for remestemcel-L mesenchymal stromal cell therapy, to be marketed as Ryoncil, for the potential treatment of steroid refractory acute graft versus host disease (GvHD).1

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of January 7, 2025, for remestemcel-L.

“We are pleased that FDA has accepted our BLA resubmission for review, and look forward to the potential approval of RYONCIL for children with SR-aGVHD,” Silviu Itescu, MBBS, FRACP, chief Executive Officer and Managing Director, Mesoblast, said in a statement.1

Mesoblast resubmitted its BLA for remestemcel-L on July 8, 2024, after 2 prior BLA submissions.2 In March 2024, the FDA informed Mesoblast that the available data from the phase 3 MSB-GVHD001 clinical trial (NCT02336230), including new requested Chemistry, Manufacturing, and Control (CMC) information previously requested, were sufficient for a BLA resubmission. The new data provided further evidence from potency assays demonstrating a suitable link between product used for the pediatric indication to the adult indication.3

Mesoblast met with the FDA after receiving a complete response letter (CRL) from the agency after reviewing remestemcel-L's biologics license application (BLA) in August. This marked the second CRL Mesoblast had received for the therapy after originally submitting a BLA in 2020.4 Mesoblast had a Type A meeting with the FDA in September 2023 that led to plans including conducting an additional single-arm trial.5

READ MORE: Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention

"We had a very productive meeting with the FDA’s review team, allowing us to establish the path forward for potential approval of remestemcel-L in SR-aGVHD. We are gathering the additional potency assay data required to demonstrate the ability of Mesoblast’s potency assay to show both the product used in the Phase 3 trial in children and the product made for commercial release are standardized,” Itescu said in an earlier statement.“ In parallel, we are focused on initiating a registration trial in adults in partnership with world-leading investigators at the Blood and Marrow Clinical Trials Network.”

Mesoblast previously announced data from the phase 3 trial were released in November 2022 and demonstrated the long-term survival benefit in treated children through 4 years. These children had an overall survival (OS) rate of 63% at 1 year, 51% at 2 years, and 49% at 4 years (median, 2-3 years) in comparison to recently published control data in children and adults (using best available therapy or ruoxitinib for adults) in which OS rate was 40-49% at 1 year and 25-38% at 2 years (median, 6.5-11.1 months). The comparison also favors the study cohort, since 88% of these children had severe disease with the highest mortality risk, defined by either IBMTR Grade C/D or Glucksberg Grade 3/4, compared to 22% to 68% of patients in control studies having severe disease.5

“These exciting long-term results provide further evidence of remestemcel-L’s potential as a highly effective treatment for SR-aGVHD in children” principal investigator Joanne Kurtzberg, MD, Jerome Harris Distinguished Professor of Pediatrics and Professor of Pathology, Duke University Medical Center, commented on the data.“Responses are durable, reducing mortality of this often lethal complication of hematopoietic stem cell transplantation.”

REFERENCES
1. FDA accepts Mesoblast’s biologics license application (BLA) for Ryoncil® in children with steroid-refractory acute graft-versus host disease (SR-aGVHD). https://investorsmedia.mesoblast.com/static-files/9a696437-abbb-4183-822f-9f74c1da5504
2. United States Food & Drug Administration (FDA) notifies mesoblast that available clinical data from phase 3 trial appear sufficient to support BLA submission for remestemcel-L in children with steroid refractory acute graft versus host disease (SR-aGVHD). News release. Mesoblast Limited. March 25, 2024. Accessed March 26, 2024. https://investorsmedia.mesoblast.com/static-files/cbb18b5c-3dea-42bf-877d-599dcc242c44
3. Mesoblast receives complete response from U.S. Food and Drug
Administration for biologics license application for steroidrefractory acute graft versus host disease in children. News release. Mesoblast Limited. Accessed August 4, 2023. https://investorsmedia.mesoblast.com/static-files/422cd6da-a0b9-49cf-a177-7fd106f111f2
4. Mesoblast receives complete response letter from the FDA for biologics license application for steroid-refractory acute graft versus host disease in children. News release. Mesoblast. October 1, 2020. https://www.asx.com.au/asxpdf/20201002/pdf/44n8xx22956c1c.pdf
5. Key outcomes from FDA Type A meeting and Mesoblast next steps to achieve RYONCIL approval. News release. Mesoblast. September 21, 2023. https://www.globenewswire.com/news-release/2023/09/21/2746995/0/en/Key-Outcomes-From-FDA-Type-A-Meeting-and-Mesoblast-Next-Steps-to-Achieve-RYONCIL-Approval.html
6. Children treated with remestemcel-L show long-term survival through four years in steroid-refractory acute graft versus host disease (SR-aGVHD). News release. Mesoblast. November 22, 2022. https://investorsmedia.mesoblast.com/static-files/41576351-fa4d-4e1c-93ad-2b822145238f
Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
Michael Severino on In Vivo Gene Editing With RNA Gene Writers
Chris Wright, MD, PhD, on Annelloviruses, a Potential Alternative to AAV for Gene Therapy
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Jacques Galipeau, MD, on Exponential Progress With Cell and Gene Therapy
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Related Content
© 2024 MJH Life Sciences

All rights reserved.